A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs SAR-439859 (Primary) ; Palbociclib
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
- 10 Oct 2018 Planned End Date changed from 17 Sep 2020 to 21 Oct 2020.
- 10 Oct 2018 Planned primary completion date changed from 17 Sep 2020 to 21 Oct 2020.
- 31 Aug 2018 Biomarkers information updated